Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Khatri, Amit
Cobbina, Enoch
Cheng, Shen
Abutarif, Malaz
Garimella, Tushar
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] Syndax Pharmaceutials Inc, Waltham, MA USA
[3] Metrum Res Grp, Tariffville, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20537
引用
收藏
页数：1
相关论文
共 50 条
  • [1] T-DXd effective in HER2-mutant NSCLC
    Peter Sidaway
    [J]. Nature Reviews Clinical Oncology, 2021, 18 : 748 - 748
  • [2] T-DXd effective in HER2-mutant NSCLC
    Sidaway, Peter
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) : 748 - 748
  • [3] Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Polhamus, Daniel
    Cobbina, Enoch
    Garcia, Ramon
    Yoder, Todd
    Abutarif, Malaz
    Garimella, Tushar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
    Li, Bob T.
    Smit, Egbert F.
    Goto, Yasushi
    Nakagawa, Kazuhiko
    Udagawa, Hibiki
    Mazieres, Julien
    Nagasaka, Misako
    Bazhenova, Lyudmila
    Saltos, Andreas N.
    Felip, Enriqueta
    Pacheco, Jose M.
    Perol, Maurice
    Paz-Ares, Luis
    Saxena, Kapil
    Shiga, Ryota
    Cheng, Yingkai
    Acharyya, Suddhasatta
    Vitazka, Patrik
    Shahidi, Javad
    Planchard, David
    Janne, Pasi A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03): : 241 - 251
  • [5] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
    Janne, Pasi A.
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    De langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Goto, Koichi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
    Goto, K.
    Sang-We, K.
    Kubo, T.
    Goto, Y.
    Ahn, M-J.
    Planchard, D.
    Kim, D-W.
    Yang, J. C-H.
    Yang, T-Y.
    Pereira, K. M. C.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Aregay, M.
    Janne, P. A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
  • [7] Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer
    O'Rourke, Kate
    [J]. CANCER, 2022, 128 (05) : 938 - 938
  • [8] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [9] FDA Gives Nod to T-DXd for HER2-Mutant NSCLC
    Osterweil, Neil
    [J]. CANCER DISCOVERY, 2022, 12 (10) : 2224 - 2224
  • [10] Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
    Vathiotis, Ioannis A.
    Bafaloukos, Dimitrios
    Syrigos, Konstantinos N. N.
    Samonis, George
    [J]. CANCERS, 2023, 15 (04)
12345